林业发展局批准了首个用于减重的口服Wegovy药丸,显示试验中平均体重减幅为13.6%。 The FDA approved the first oral Wegovy pill for weight loss, showing 13.6% average weight loss in trials.

美国林业发展局已经批准了第一种口服避孕药,即Wegovy(Wegovy),这是诺沃·诺迪斯克(Novo Nordisk)生产的GLP-1减重药物,供肥胖或超重的成年人和与体重有关的健康状况使用。 The U.S. FDA has approved the first oral pill form of Wegovy, a GLP-1 weight-loss drug made by Novo Nordisk, for adults with obesity or overweight with weight-related health conditions. 每日服用一次的含有25mg的西马格卢提德片,是为了与饮食和运动一起使用,在临床试验中显示平均体重减轻13. 6%. The once-daily tablet, containing 25 mg of semaglutide, is intended to be used with diet and exercise and showed an average 13.6% body weight loss in clinical trials. 它获得批准是为了帮助管理体重和减少发生重大心血管事件的风险。 It is approved to help manage weight and reduce the risk of major cardiovascular events. 药丸必须用一小口水空着肚子吃,然后在吃之前等30分钟。 The pill must be taken on an empty stomach with a sip of water, followed by a 30-minute wait before eating. 预计它将于2026年1月初启动,一些供应商的起始价为每月149美元。 It is expected to launch in early January 2026, with a starting price of $149 per month for some providers. 此项批准标志着向更方便、非注射性肥胖治疗的重大转变。 The approval marks a significant shift toward more accessible, non-injectable obesity treatments.